Guild stock up by beating expectations from Gilead Science revenue; Reduces Outlook | Investors’ business daily

Late wednesday Gilead Sciences (GILD) reported earnings and sales that topped analysts’ estimates. Guild stocks remained low after a rebound in expanded trade for the first time, although the pharmaceutical company underestimated it. X U.S. The manufacturer of the only Covid-19 treatment approved by the Food and Drug Administration reported …

Read More »